Although many reports have noted the synergy between EPO and G-CSF in the treatment of anemia in myelodysplastic syndromes (MDS) [16], [18], investigators did not propose any mechanism to explain the results of clinical trial. This evidence concerns the gene CSF3 and anemia (phenotype).